AU2020313930A1 - Pharmaceutical formulations containing gaboxadol for therapeutic treatment - Google Patents

Pharmaceutical formulations containing gaboxadol for therapeutic treatment Download PDF

Info

Publication number
AU2020313930A1
AU2020313930A1 AU2020313930A AU2020313930A AU2020313930A1 AU 2020313930 A1 AU2020313930 A1 AU 2020313930A1 AU 2020313930 A AU2020313930 A AU 2020313930A AU 2020313930 A AU2020313930 A AU 2020313930A AU 2020313930 A1 AU2020313930 A1 AU 2020313930A1
Authority
AU
Australia
Prior art keywords
gaboxadol
pharmaceutically acceptable
acceptable salt
drug
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020313930A
Other languages
English (en)
Inventor
Matthew During
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of AU2020313930A1 publication Critical patent/AU2020313930A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020313930A 2019-07-15 2020-07-15 Pharmaceutical formulations containing gaboxadol for therapeutic treatment Abandoned AU2020313930A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874152P 2019-07-15 2019-07-15
US62/874,152 2019-07-15
PCT/US2020/042044 WO2021011597A1 (en) 2019-07-15 2020-07-15 Pharmaceutical formulations containing gaboxadol for therapeutic treatment

Publications (1)

Publication Number Publication Date
AU2020313930A1 true AU2020313930A1 (en) 2022-02-03

Family

ID=74211193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020313930A Abandoned AU2020313930A1 (en) 2019-07-15 2020-07-15 Pharmaceutical formulations containing gaboxadol for therapeutic treatment

Country Status (10)

Country Link
US (3) US20210015760A1 (https=)
EP (1) EP3982937A4 (https=)
JP (1) JP2022540917A (https=)
KR (1) KR20220035195A (https=)
CN (2) CN114173765A (https=)
AU (1) AU2020313930A1 (https=)
CA (1) CA3146737A1 (https=)
IL (1) IL289657A (https=)
MX (1) MX2022000663A (https=)
WO (1) WO2021011597A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62007B1 (sr) * 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
CA2951497C (en) * 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法

Also Published As

Publication number Publication date
MX2022000663A (es) 2022-02-16
US20220040120A1 (en) 2022-02-10
CN114173765A (zh) 2022-03-11
IL289657A (en) 2022-03-01
WO2021011597A1 (en) 2021-01-21
US20240252447A1 (en) 2024-08-01
CN118141810A (zh) 2024-06-07
CA3146737A1 (en) 2021-01-21
EP3982937A1 (en) 2022-04-20
KR20220035195A (ko) 2022-03-21
JP2022540917A (ja) 2022-09-20
EP3982937A4 (en) 2022-08-10
US20210015760A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
JP2026063249A (ja) 注意欠陥障害の処置のための方法および組成物
JPH08505633A (ja) ニコチン依存症治療のための薬学的処方
JP2011515485A (ja) ロフェキシジンを経粘膜送達するための組成物およびその方法
US20200222372A1 (en) Use of gaboxadol in the treatment of narcolepsy
JP2008540437A (ja) キニーネを含有する制御放出調合剤
US20240252447A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
AU2018285927B2 (en) Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
NZ747702A (en) Melatonin mini-tablets and method of manufacturing the same
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
JP2007509031A (ja) ガランタミンの口腔用製剤およびその使用
Sakthivel et al. A Textbook of Novel Drug Delivery Systems
CN101227907A (zh) 含奎宁控释制剂
AU2019405489A1 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application